TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22392497

Group type: EXPERIMENTAL
Intervention: Peach shake meal (PSM) (SA: 0.06 ± 0.001 mg/100 g)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Peach shake meal (PSM)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Mixed sugar meal (MSM)
Number of subjects: 26
Study: 15774433

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT), 12-14 sessions
Number of subjects: 30

Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT)
Number of subjects: 30
Study: 12005157

Group type: EXPERIMENTAL
Intervention: 4-min vibration intervention
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 16
Study: 9469276

Group type: EXPERIMENTAL
Intervention: Intraumbilical oxytocin (20 IU in 20 mL of saline)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Intraumbilical saline (20 mL)
Number of subjects: 81
Study: 8535640

Group type: EXPERIMENTAL
Intervention: Combination of sulphasalazine (SASP) and methotrexate (MTX)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Methotrexate (MTX)
Number of subjects: 40
Study: 2404049

Group type: EXPERIMENTAL
Intervention: Low-fat diet intervention (15% of energy intake) with bi-weekly individual counseling sessions
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Low-fat diet intervention
Number of subjects: 17
Study: 389817

Group type: EXPERIMENTAL
Intervention: Co-trimazine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nitrofurantoin
Number of subjects: 0
Study: 11483335

Group type: EXPERIMENTAL
Intervention: Androgen ablation (goserelin 3.6 mg every 4 weeks and flutamide 250 mg t.i.d. for 2 months before and during radiation therapy)
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Androgen ablation (goserelin and flutamide)
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Androgen ablation (goserelin and flutamide) in patients with Gleason score 2‐‐6
Number of subjects: 456

Group type: COMPARATOR
Intervention: Radiation therapy alone
Number of subjects: 456
Study: 31348227

Group type: EXPERIMENTAL
Intervention: Specific exercise program (12 weeks duration)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Nonspecific exercises performed at home
Number of subjects: 94
Study: 28682136

Group type: EXPERIMENTAL
Intervention: Social intervention group
Number of subjects: 222

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 222
Study: 27439975

Group type: EXPERIMENTAL
Intervention: Adjuvant chemoradiotherapy limited to the mesorectum
Number of subjects: 302

Group type: COMPARATOR
Intervention: Standard completion total mesorectal excision (TME)
Number of subjects: 302
Study: 23429621

Group type: EXPERIMENTAL
Intervention: Bimatoprost/timolol (BTFC)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Travoprost/timolol (TTFC)
Number of subjects: 80
Study: 22035851

Group type: EXPERIMENTAL
Intervention: Indacaterol (150 μg)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Tiotropium (18 μg)
Number of subjects: 49
Study: 21225011

Group type: EXPERIMENTAL
Intervention: Preseasonal prophylactic treatment with antihistamines (2-4 weeks before pollen season)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 0
Study: 16904960

Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 70

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 70
Study: 15784793

Group type: EXPERIMENTAL
Intervention: Pre-screening assessment
Number of subjects: 3535

Group type: EXPERIMENTAL
Intervention: Post-screening assessment
Number of subjects: 3535

Group type: EXPERIMENTAL
Intervention: Overall assessment
Number of subjects: 3535
Study: 12486618

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 600 mg twice daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard antibiotic therapy
Number of subjects: 24
Study: 9869174

Group type: EXPERIMENTAL
Intervention: Diet enriched in monounsaturated fat (MUFA) for 3 weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Carbohydrate-enriched control diet
Number of subjects: 12
Study: 7637479

Group type: EXPERIMENTAL
Intervention: SPf66 malaria vaccine
Number of subjects: 630

Group type: COMPARATOR
Intervention: Injected polio vaccine (IPV)
Number of subjects: 630
Study: 2491766

Group type: EXPERIMENTAL
Intervention: Corticosteroids plus thyrotropin-releasing hormone (TRH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Corticosteroids
Number of subjects: 0
Study: 870513

Group type: EXPERIMENTAL
Intervention: Ovine prolactin (25 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (1 ml normal saline)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ovine prolactin (100 mg)
Number of subjects: 8
Study: 30041576

Group type: EXPERIMENTAL
Intervention: Smartphone-based measures of cell phone use while driving
Number of subjects: 16
Study: 27020911

Group type: EXPERIMENTAL
Intervention: 2% articaine
Number of subjects: 95

Group type: COMPARATOR
Intervention: 4% articaine
Number of subjects: 95
Study: 26666324

Group type: EXPERIMENTAL
Intervention: Novel oral anticoagulants (NOACs) including dabigatran etexilate, rivaroxaban, apixaban, and edoxaban.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Classic anticoagulants like heparin, low‐molecular‐weight heparins (LMWHs), fondaparinux, and vitamin K antagonists.
Number of subjects: 0
Study: 24037563

Group type: EXPERIMENTAL
Intervention: Standard verbal feedback plus video (group 1)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standard verbal feedback alone (group 2)
Number of subjects: 48
Study: 21199290

Group type: EXPERIMENTAL
Intervention: 200 mcg sublingual misoprostol
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 400 mcg sublingual misoprostol
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 600 mcg sublingual misoprostol
Number of subjects: 49

Group type: COMPARATOR
Intervention: Intramuscular oxytocin (10 IU)
Number of subjects: 49
Study: 18635671

Group type: EXPERIMENTAL
Intervention: Kneeling advice and education
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine care (no specific kneeling advice)
Number of subjects: 60
Study: 16409193

Group type: EXPERIMENTAL
Intervention: Grass allergen tablet (SQ-T) at various doses (25,000 to 1,000,000 standardized quality tablet)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Grass allergen tablet (SQ-T)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 12744860

Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccine (5 doses)
Number of subjects: 505

Group type: COMPARATOR
Intervention: Whole‐cell pertussis vaccine (5 doses)
Number of subjects: 505
Study: 10561296

Group type: EXPERIMENTAL
Intervention: Docetaxel 100 mg/m(2) every 3 weeks
Number of subjects: 326

Group type: COMPARATOR
Intervention: Doxorubicin 75 mg/m(2) every 3 weeks
Number of subjects: 326
Study: 8739678

Group type: EXPERIMENTAL
Intervention: latanoprost 0.005% once daily (morning dose)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: latanoprost 0.005% once daily (evening dose)
Number of subjects: 31

Group type: COMPARATOR
Intervention: timolol 0.5% twice daily
Number of subjects: 31
Study: 1820640

Group type: EXPERIMENTAL
Intervention: 7-day regimen of oral artesunate at 600 mg
Number of subjects: 89

Group type: COMPARATOR
Intervention: 5-day regimen of oral artesunate at 600 mg
Number of subjects: 89
Study: 6755786

Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) 325 mg and placebo
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) and dipyridamole (DIP) 325 mg and 75 mg
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) alone
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) and dipyridamole (DIP)
Number of subjects: 49
Study: 31361815

Group type: EXPERIMENTAL
Intervention: Supportive text messages (twice-daily) over 6 months
Number of subjects: 95

Group type: COMPARATOR
Intervention: Treatment as usual for 6 months
Number of subjects: 95
Study: 29032666

Group type: EXPERIMENTAL
Intervention: Fimasartan 30 mg
Number of subjects: 75

Group type: COMPARATOR
Intervention: Valsartan 80 mg
Number of subjects: 75
Study: 25933913

Group type: EXPERIMENTAL
Intervention: New CPAP
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Bi-level PAP
Number of subjects: 28

Group type: COMPARATOR
Intervention: Subjective and objective measures of sleepiness
Number of subjects: 28
Study: 23102885

Group type: EXPERIMENTAL
Intervention: Thrombolysis group (TG) - low-dose tissue plasminogen activator plus anticoagulation (n=61)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control group (CG) - anticoagulation alone (n=60)
Number of subjects: 121
Study: 21689098

Group type: EXPERIMENTAL
Intervention: Financial incentive of U.S.$20 to bring in the intervention letter to their provider
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Financial incentives
Number of subjects: 54
Study: 17607304

Group type: EXPERIMENTAL
Intervention: Goserelin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant androgen deprivation therapy
Number of subjects: 0
Study: 16876666

Group type: EXPERIMENTAL
Intervention: Continuous venovenous haemodiafiltration
Number of subjects: 360

Group type: COMPARATOR
Intervention: Intermittent haemodialysis
Number of subjects: 360
Study: 12627042

Group type: EXPERIMENTAL
Intervention: 17beta-estradiol
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 56
Study: 10704610

Group type: EXPERIMENTAL
Intervention: Endothelium-dependent vasodilatation
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Endothelium-independent vasodilatation
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Flow-mediated dilation (FMD)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Extent of FMD
Number of subjects: 71
Study: 9625844

Group type: EXPERIMENTAL
Intervention: Val/Val genotype
Number of subjects: 57

Group type: COMPARATOR
Intervention: Other genotypes (Ala/Ala and Ala/Aal)
Number of subjects: 57
Study: 7875267

Group type: EXPERIMENTAL
Intervention: Salmeterol (50 micrograms)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Salbutamol (200 micrograms)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 2827456

Group type: EXPERIMENTAL
Intervention: Wheat bran (30 g added to formula meal)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: California small white beans
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: PteGlu (1.13 mumol)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: PteGlu7 (1.13 mumol)
Number of subjects: 6
Study: 28809383

Group type: EXPERIMENTAL
Intervention: Full-dose α-galactosidase (300 GALU)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Half-dose α-galactosidase (150 GALU)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (glucose)
Number of subjects: 31
Study: 28137316

Group type: EXPERIMENTAL
Intervention: time‐intensive cognitive‐behaviour therapy (iCBT)
Number of subjects: 34

Group type: COMPARATOR
Intervention: treatment as usual (TAU)
Number of subjects: 34

Group type: COMPARATOR
Intervention: healthy control group
Number of subjects: 34
Study: 25639732

Group type: EXPERIMENTAL
Intervention: Gestalt and lucid dreaming group therapy (LDG)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Gestalt therapy group (GTG)
Number of subjects: 32
Study: 23061978

Group type: EXPERIMENTAL
Intervention: PVI-guided fluid management
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21
Study: 19766503

Group type: EXPERIMENTAL
Intervention: High-flow, low-resistance (HFLR) technique
Number of subjects: 48

Group type: COMPARATOR
Intervention: Normal-flow technique
Number of subjects: 48
Study: 18374458

Group type: EXPERIMENTAL
Intervention: Seal oil (10 mL, 3 times a day for 14 days)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Cod liver oil (10 mL, 3 times a day for 14 days)
Number of subjects: 38
Study: 16685542

Group type: EXPERIMENTAL
Intervention: Topical furosemide (6.6 mmol/l solution)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Oral methylprednisolone (1 mg/kg/day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 40
Study: 12404674

Group type: EXPERIMENTAL
Intervention: Tryptophan Depletion (TD)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Tyrosine Depletion (TPD)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Balanced-Control Condition (B)
Number of subjects: 13
Study: 9539519

Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 199

Group type: COMPARATOR
Intervention: Boluses of meperidine
Number of subjects: 199
Study: 7840074

Group type: EXPERIMENTAL
Intervention: Lactobacillus gasseri (ADH)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Streptococcus thermophilus and Lactobacillus bulgaricus
Number of subjects: 33
Study: 1982576

Group type: EXPERIMENTAL
Intervention: Teicoplanin
Number of subjects: 113

Group type: COMPARATOR
Intervention: Cephradine combined with metronidazole
Number of subjects: 113
Study: 366741

Group type: EXPERIMENTAL
Intervention: 2.5 mg terbutaline
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 5.0 mg terbutaline
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 6121138

Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Untreated
Number of subjects: 50
Study: 30874775

Group type: EXPERIMENTAL
Intervention: Light physical activity (PA) measured by accelerometry
Number of subjects: 5861
Study: 29210507

Group type: EXPERIMENTAL
Intervention: Iron and folic acid syrup (IFAS) administered twice weekly for 1 month
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Multiple micronutrient powders (MNPs) for 1 month
Number of subjects: 100
Study: 26875894

Group type: EXPERIMENTAL
Intervention: Argon plasma coagulation combined high frequency electric knife therapy
Number of subjects: 56

Group type: COMPARATOR
Intervention: High frequency electric band ligation electroexcision
Number of subjects: 56
Study: 23709097

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILS)
Number of subjects: 3210

Group type: EXPERIMENTAL
Intervention: Metformin (MET)
Number of subjects: 3210

Group type: COMPARATOR
Intervention: Placebo (PLB)
Number of subjects: 3210
Study: 21872537

Group type: EXPERIMENTAL
Intervention: Personalized interventions developed using the Treatment Routes for Exploring Agitation decision tree protocol
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Successful interventions presented after the feasibility period
Number of subjects: 89
Study: 19421022

Group type: EXPERIMENTAL
Intervention: Novel ocular lubricant
Number of subjects: 110

Group type: COMPARATOR
Intervention: Marketed ocular lubricant
Number of subjects: 110
Study: 17341510

Group type: EXPERIMENTAL
Intervention: Highest Brink scale scores (n=75)
Number of subjects: 317

Group type: COMPARATOR
Intervention: Lowest Brink scale scores (n=56)
Number of subjects: 317
Study: 15965635

Group type: EXPERIMENTAL
Intervention: Spa therapy (n = 16) for 2 weeks in addition to medical treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (n = 14) continued medical treatment and/or daily exercises
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Spa therapy (n = 16)
Number of subjects: 30
Study: 11896092

Group type: EXPERIMENTAL
Intervention: 4 x DOC (100 mg/m(2))
Number of subjects: 162

Group type: COMPARATOR
Intervention: 4 x CVAP
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: 4 x DOC (for nonresponders)
Number of subjects: 162
Study: 10207925

Group type: EXPERIMENTAL
Intervention: Acetazolamide (ACZ) and furosemide (FUR) treatment
Number of subjects: 16

Group type: COMPARATOR
Intervention: Serial lumbar puncture (LP)
Number of subjects: 16
Study: 8568782

Group type: EXPERIMENTAL
Intervention: Active smoking
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Passive smoking
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cigarette smoking
Number of subjects: 0
Study: 2222823

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 104570

Group type: EXPERIMENTAL
Intervention: Meglumine iodamide 24%
Number of subjects: 283

Group type: COMPARATOR
Intervention: Meglumine diatrizoate 30%
Number of subjects: 283
Study: 30447156

Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: verapamil
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ranolazine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: chloroquine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: diltiazem
Number of subjects: 30
Study: 29110972

Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg added to insulin glargine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo added to insulin glargine
Number of subjects: 0
Study: 27567670

Group type: EXPERIMENTAL
Intervention: Modified (new technique) stitch
Number of subjects: 160

Group type: COMPARATOR
Intervention: Classic technique (B-Lynch suture)
Number of subjects: 160
Study: 25143061

Group type: EXPERIMENTAL
Intervention: Motivational interviewing intervention for 3 months after CHT
Number of subjects: 169
Study: 22020607

Group type: EXPERIMENTAL
Intervention: Epidural administration of 10 mg of etanercept and 2.0 mL of lidocaine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Epidural administration of 3.3 mg of dexamethasone and 2.0 mL of lidocaine
Number of subjects: 80
Study: 19328352

Group type: EXPERIMENTAL
Intervention: Endoscopic dacryocystorhinostomy with silicone intubation
Number of subjects: 38

Group type: COMPARATOR
Intervention: Endoscopic dacryocystorhinostomy without silicone intubation
Number of subjects: 38
Study: 17761319

Group type: EXPERIMENTAL
Intervention: Active extracorporeal shockwave therapy (0.25 mJ/mm(2))
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham shockwave therapy
Number of subjects: 40
Study: 15066896

Group type: EXPERIMENTAL
Intervention: QI-meds and QI-therapy
Number of subjects: 1356

Group type: EXPERIMENTAL
Intervention: QI-therapy
Number of subjects: 1356

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1356
Study: 12098059

Group type: EXPERIMENTAL
Intervention: Antiseptic wound wick (povidone-iodine soaked ribbon gauze)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Subcuticular wound closure
Number of subjects: 174
Study: 10436094

Group type: EXPERIMENTAL
Intervention: Stroke Unit (SU)
Number of subjects: 220

Group type: COMPARATOR
Intervention: General Wards (GW)
Number of subjects: 220
Study: 8664455

Group type: EXPERIMENTAL
Intervention: Dobutamine (7 micrograms/kg/min)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Insulin (1.5 U/kg/h)
Number of subjects: 2
Study: 1972963

Group type: EXPERIMENTAL
Intervention: Sunflowerseed oil (60 ml/day)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Linseed oil (60 ml/day)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Olive oil (60 ml/day)
Number of subjects: 44
Study: 369924

Group type: EXPERIMENTAL
Intervention: Indoprofen 800 mg/day
Number of subjects: 24

Group type: COMPARATOR
Intervention: Indomethacin 80 mg/day
Number of subjects: 24
Study: 30852257

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 27461773

Group type: EXPERIMENTAL
Intervention: Onartuzumab plus paclitaxel plus carboplatin/cisplatin
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo plus paclitaxel plus carboplatin/cisplatin
Number of subjects: 109
Study: 27003895

Group type: EXPERIMENTAL
Intervention: Single subcutaneous injection of FE 999049 at doses of 37.5, 75, 150, 225, or 450 IU
Number of subjects: 27
Study: 24480729

Group type: EXPERIMENTAL
Intervention: Intervention group (HOME Plus program)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (attention-only)
Number of subjects: 0
Study: 22958287

Group type: EXPERIMENTAL
Intervention: Taurolidine
Number of subjects: 48

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 48
Study: 19278583

Group type: EXPERIMENTAL
Intervention: Ulinastatin and thymosin alpha1, 200 kU IV twice a day for 4 days, then 100 kU for 6 days; thymosin alpha1, 1.6 mg subcutaneous twice a day for 4 days, then 1.6 mg per day for 6 days.
Number of subjects: 242

Group type: COMPARATOR
Intervention: Control group received conventional treatment according to Surviving Sepsis Campaign (SSC) 2004.
Number of subjects: 242
Study: 17404794

Group type: EXPERIMENTAL
Intervention: T2-T3 ablation
Number of subjects: 25

Group type: COMPARATOR
Intervention: T2 ablation
Number of subjects: 25
Study: 15637978

Group type: EXPERIMENTAL
Intervention: Novel integrated power toothbrush and toothpaste system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonintegrated power toothbrush and regular toothpaste
Number of subjects: 0
Study: 11480461

Group type: EXPERIMENTAL
Intervention: 0.5% tetracaine in 10% glucose with 0.025% phenylephrine (group P)
Number of subjects: 64

Group type: COMPARATOR
Intervention: 0.5% tetracaine in 10% glucose (group C)
Number of subjects: 64
Study: 9683957

Group type: EXPERIMENTAL
Intervention: Lodoxamide 0.1%
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate (DCG) 2%
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fluorometholone 0.1%
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 30
Study: 7935897

Group type: EXPERIMENTAL
Intervention: Group C (received a list with actual medication and recommendations by the pharmacist)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Group A (control group, sent prescriptions as before)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Group B (received a list with medication used by their patients)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Group C
Number of subjects: 196
Study: 3363024

Group type: EXPERIMENTAL
Intervention: Sodium lactate infusion
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Isoproterenol infusion
Number of subjects: 131

Group type: COMPARATOR
Intervention: Lactate-induced panic attacks in controls
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Lactate-induced panic attacks in patients
Number of subjects: 131
Study: 29246950

Group type: EXPERIMENTAL
Intervention: Semaglutide 1.0 mg
Number of subjects: 813

Group type: COMPARATOR
Intervention: Exenatide ER 2.0 mg
Number of subjects: 813
Study: 27481188

Group type: EXPERIMENTAL
Intervention: Transarterial chemoembolization (TACE) with bicarbonate local infusion
Number of subjects: 77

Group type: COMPARATOR
Intervention: Transarterial chemoembolization (TACE) without bicarbonate local infusion
Number of subjects: 77